Revvity Inc vs S&P Global Inc — how do they compare? Revvity Inc trades at $110.1 (market cap $11.87B), while S&P Global Inc trades at $431.29 (market cap $132.71B). The key difference: S&P Global Inc is far larger — about 11.2× Revvity Inc's market cap, and S&P Global Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals.
| RVTY | SPGI | |
|---|---|---|
Market Cap | $11.87B | $132.71B |
Sector | Technology | Financials |
52-Week High | $117.75 | $534.79 |
52-Week Low | $82.26 | $370.42 |
Enterprise Value | $14.36B | $144.68B |
Dividend Yield | 0.26% | 0.87% |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
S&P Global (SPGI) trades at $431.26, down 4.34% on the day, amid a generally bullish technical setup with strong analyst support. The company reported robust fundamentals with 2025 revenue of $15.34B and net income of $4.47B, yielding a 30.36% net margin. Recent corporate developments include the spin-off of its mobility business and new product launches in digital asset indexing and ETF analytics, signaling strategic focus and innovation.
The outlook remains positive given strong profitability, recurring revenue model, and Wall Street's consensus price target of $532.10, implying significant upside. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Earnings growth and AI-driven data demand present the primary catalysts for shareholder value appreciation.
Trailing returns across standard periods
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →